RespireRx Pharmaceuticals (RespireRx Pharmaceuticals) Effective Interest Rate on Debt % : 10.33% (As of Sep. 2023)

View and export this data going back to 2009. Start your Free Trial

What is RespireRx Pharmaceuticals Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. RespireRx Pharmaceuticals's annualized positive value of Interest Expense for the quarter that ended in Sep. 2023 was $0.29 Mil. RespireRx Pharmaceuticals's average total debt for the quarter that ended in Sep. 2023 was $2.83 Mil. Therefore, RespireRx Pharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Sep. 2023 was 10.33%.

RespireRx Pharmaceuticals Effective Interest Rate on Debt % Historical Data

The historical data trend for RespireRx Pharmaceuticals's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RespireRx Pharmaceuticals Effective Interest Rate on Debt % Chart

RespireRx Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Effective Interest Rate on Debt %

Get a 7-Day Free Trial

11.34

28.09

32.91

38.54

25.24

RespireRx Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Effective Interest Rate on Debt %	Get a 7-Day Free Trial															15.28	10.64	9.64	31.43	10.33

Competitive Comparison of RespireRx Pharmaceuticals's Effective Interest Rate on Debt %

For the Biotechnology subindustry, RespireRx Pharmaceuticals's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RespireRx Pharmaceuticals's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RespireRx Pharmaceuticals's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where RespireRx Pharmaceuticals's Effective Interest Rate on Debt % falls into.

RespireRx Pharmaceuticals Effective Interest Rate on Debt % Calculation

RespireRx Pharmaceuticals's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2022 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (A: Dec. 2021 )	+	Total Debt (A: Dec. 2022 ))	/ count )
=	-1 * -0.604	/	( (2.078	+	2.709)	/ 2 )
=	-1 * -0.604	/	2.3935
=	25.24 %

where

	Total Debt (A: Dec. 2021 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0	+	2.078
=	2.078

	Total Debt (A: Dec. 2022 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0	+	2.709
=	2.709

RespireRx Pharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Sep. 2023 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (Q: Jun. 2023 )	+	Total Debt (Q: Sep. 2023 ))	/ count )
=	-1 * -0.292	/	( (2.873	+	2.781)	/ 2 )
=	-1 * -0.292	/	2.827
=	10.33 %

where

	Total Debt (Q: Jun. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0	+	2.873
=	2.873

	Total Debt (Q: Sep. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0	+	2.781
=	2.781

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Sep. 2023) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

RespireRx Pharmaceuticals (OTCPK:RSPI) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

RespireRx Pharmaceuticals Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of RespireRx Pharmaceuticals's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.

RespireRx Pharmaceuticals (RespireRx Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RespireRx Pharmaceuticals Inc (OTCPK:RSPI) » Definitions » Effective Interest Rate on Debt %

Comparable Companies

Traded in Other Exchanges

N/A

Address

126 Valley Road, Suite C, Glen Rock, NJ, USA, 07452

Website

http://www.respirerx.com

RespireRx Pharmaceuticals Inc is engaged in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. The pipeline products of the company are dronabinol which is developed for the treatment of OSA (Obstructive Sleep Apnea), a form of sleep apnea; CX1739 for the treatment of chronic central sleep apnea; CX717 and CX1942 is an injectable dosage for respiratory depression or vaso-occlusive passes associated with sickle cell disease. The company also focuses on developing another class of compounds called ampakines for the treatment of various respiratory disorders.

Executives

David Dickason	officer: SVP of Pre-Clinical Prod. Dev.	126 VALLEY ROAD, SUITE C, GLEN ROCK NJ 07452
Timothy L. Jones	director, officer: CEO and President	126 VALLEY ROAD, SUITE C, GLEN ROCK NJ 07452
Manuso James S J	director, officer: President & CEO	5130 ROUTE 212, WILLOW NY 12495
Katie Macfarlane	director	101 POOR FARM ROAD 3RD FLOOR, PRINCETON NJ 08540
Purcell Richard David Jr.	officer: SVP - Research & Deleopment	65 FAIR HAVEN ROAD, FAIR HAVEN NJ 07704
James Sapirstein	director	1517 SAN JACINTO, HOUSTON TX 77002
Marc M Radin	officer: Controller	33 FRANKLIN PLACE, GLEN ROCK NJ 07452
Robert N Weingarten	director, officer: Vice President and CFO	5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367
Aurora Capital Llc	other: Member of a 10% owner group	354 WIDOW GAVITS ROAD, PO BOX 1167, BRIDGEHAMPTON, NY 11932-1167
Aurora Capital Corp	other: Member of 10% owner group
Jeff Eliot Margolis	director, officer: Vice President, Sec. & Treas., other: Member of 10% owner group	C/O AURORA CAPITAL LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016
Steven Chizzik	other: Member of 10% owner group	C/O THE VERRAZANO GROUP, LLC, 2204 MORRIS AVENUE, SUITE 203A, UNION NJ 07083
Arnold Lippa	director, officer: Chairman, CEO and President, other: Member of 10% owner group	C/O AURORA CAPITAL, LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016
T. Morgen Capital Llc	other: Member of 10% owner group	C/O AURORA CAPITAL LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016
Kenneth M Cohen	other: Member of 10% owner group	12750 HIGH BLUFF DRIVE, SUITE 310, SAN DIEGO CA 92130